The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

Becomes the first subcutaneously administered PD-1 inhibitor.

Halozyme announced that Argenx’s Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Hea ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and ...

Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

Furthermore, Halozyme's track record of securing regulatory approvals for its Enhanze-coformulated products supports the firm's optimistic outlook. The company's strong performance is reflected in ...

The firm believes Halozyme remains well-positioned for future growth, thanks to its royalty streams from the ENHANZE-coformulated products pipeline. The analyst emphasized that their positive ...